Shanghai Fosun Pharmaceutical Subsidiary Signs Cooperation, License Deal

MT NewswiresDec 20 16:28

HENLIUS (02696.HK) has entered into a collaboration and licensing agreement with Palleon.

HENLIUS (02696.HK) announced a collaboration and licensing agreement with Palleon, whereby both parties agree to global collaborative development and commercialization in their respective licensed regions for E-602 and combination therapy for the treatment of human diseases. This collaboration does not involve an upfront payment, with the company set to pay Palleon milestone payments totaling no more than 95.3 million USD, along with royalties calculated at 8%-12% of annual net sales.

AASTOCKSDec 20 00:30

The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."

In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.

cls.cnDec 19 22:27

FOSUN PHARMA (600196.SH) has signed a cooperation and licensing agreement with Palleon, intending to carry out joint clinical research on the licensed product Hanlikang.

FOSUN PHARMA (600196.SH) announced that its controlling subsidiary HENLIUS signed an agreement with Palleon...

Zhitong FinanceDec 19 18:27

FOSUN PHARMA (600196.SH): A subsidiary has signed a licensing agreement.

Gelonghui, December 19 - FOSUN PHARMA (600196.SH) announced that on December 19, 2024, its holding subsidiary HENLIUS signed a "Cooperation and License Agreement" with Palleon. According to the agreement, both parties will collaborate on the global development of Palleon’s investigational product E-602 and related combination therapy solutions within the field (i.e., for the treatment of human diseases) based on their respective patents and proprietary technologies, and will carry out commercialization in their respective licensed areas.

Gelonghui FinanceDec 19 18:11

Shanghai Fosun Pharma Moves Hong Kong Office

TipRanksDec 19 17:13